Evaluation of cord blood alkaline phosphatase as a predictor of hyperbilirubinemia in Egyptian neonates

Abstract EN

Background/aim Hyperbilirubinemia is a major cause of neonatal morbidity.

It affects nearly 60% of term and 80% of preterm neonates during the first week of life.

Early prediction of hyperbilirubinemia will help in early discharge and prevent hospitalization of babies and mothers for longer periods.

The aim of this study was to verify whether the cord alkaline phosphatase (ALP) levels can predict the development of neonatal hyperbilirubinemia.

Participants and methods This prospective study was conducted at Alglaa Teaching Hospital from June 2016 to May 2018.

A total of 200 healthy term and late preterm neonates meeting the inclusion criteria were enrolled in this study (gestational age >35 weeks of either sex, from any mode of delivery, and Apgar score ≥7 at first and fifth minutes of life).

After birth, cord blood was collected for the estimation of cord blood ALP and serum total bilirubin.

Results The incidence of clinical jaundice in our study was 50.54% (94 cases).

Only 28.72% (27 cases) of them required treatment.

There is a significant association between cord blood ALP levels and the development of hyperbilirubinemia requiring treatment.

Receiver operating characteristic curve analysis demonstrates that ALP level of the cord blood greater than 342 IU/l was the most appropriate cutoff value for predicting significant jaundice (that needs treatment).

It was associated with 91.07% sensitivity and specificity 61.54%.

The area under the curve was 0.791, indicating the high significance and the usefulness of this assay in predicting significant jaundice requiring medication.

Conclusion This study concludes that cord blood ALP levels reliably predict the occurrence of pathological hyperbilirubinemia requiring therapy as defined by the current operational guidelines.